SCHEMBL585480

SCHEMBL585480

Cc1ccc(CCC=O)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
SKP2 Q13309 1/20 0.36
KCNH2 Q12809 1/20 0.36
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
POLB P06746 1/20 0.33
NQO1 P15559 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ROCK2 O75116 1/20 0.33
CHEK2 O96017 1/20 0.33
PRKACA P17612 1/20 0.33
RPS6KB1 P23443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8827605 0.85 CDK1 (0.42) CNR1SKP2
SCHEMBL6372615 0.82 ALOX15 (0.41) ADRB2ESR1ESR2ALDH1A1LMNA
SCHEMBL585504 0.82 DAO (0.49) KMT2A
SCHEMBL6904685 0.82 SKP2 (0.37) SKP2POLBALDH1A1MEN1GAA
SCHEMBL1257233 0.82 DAO (0.49)
SCHEMBL6373228 0.82 ESR1 (0.57) CNR1ESR1ESR2ALDH1A1GAA
SCHEMBL27464297 0.81 SKP2 (0.37) CNR1SKP2ESR1ESR2ALDH1A1
SCHEMBL15609627 0.80 RAPGEF4 (0.33) ALDH1A1LMNA
SCHEMBL2560484 0.80 ALDH1A1 (0.37) CNR1POLBNQO1ESR1ESR2
SCHEMBL29597103 0.79 PTGS1 (0.45) CNR1SKP2POLBESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002632-A1 APPARATUS AND COMPOSITIONS FOR IMPROVING SCENT DELIVERY THE PROCTER AND GAMBLE COMPANY 2022-01-06 US claimed
US-20220002633-A1 APPARATUS AND COMPOSITIONS FOR IMPROVING SCENT DELIVERY THE PROCTER AND GAMBLE COMPANY 2022-01-06 US claimed
CN-113412327-A Consumer product compositions with perfume encapsulates 宝洁公司 2021-09-17 CN claimed
US-12036341-B2 Freshening compositions and methods of atomizing freshening compositions with a thermally-actuated microfluidic cartridge THE PROCTER & GAMBLE COMPANY (US) 2024-07-16 US disclosed
EP-3999344-B1 METHOD OF ATOMIZING A FLUID COMPOSITION PROCTER & GAMBLE (US) 2024-06-05 EP disclosed
WO-2024108076-A1 AEROSOL DISPENSER AND NOZZLE WITH REDUCED DRIP THE PROCTER & GAMBLE COMPANY (US) 2024-05-23 WO disclosed
US-20240166426-A1 AEROSOL DISPENSER AND NOZZLE WITH REDUCED DRIP THE PROCTER AND GAMBLE COMPANY 2024-05-23 US disclosed
WO-2024108077-A1 AEROSOL DISPENSER AND NOZZLE THE PROCTER & GAMBLE COMPANY (US) 2024-05-23 WO disclosed
US-20240166427-A1 AEROSOL DISPENSER AND NOZZLE THE PROCTER AND GAMBLE COMPANY 2024-05-23 US disclosed
EP-3431143-B1 GELS COMPRISING A HYDROPHOBIC MATERIAL PROCTER & GAMBLE INT OPERATIONS SA (CH) 2024-02-28 EP disclosed
EP-3431144-B1 GELS COMPRISING A HYDROPHOBIC MATERIAL PROCTER & GAMBLE INT OPERATIONS SA (CH) 2023-06-14 EP disclosed
US-20100111889-A1 Malodor Control System PROCTER & GAMBLE COMPANY, THE 2010-05-06 US disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
EP-2125823-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 EP disclosed
CN-101568542-A 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-10-28 CN disclosed
US-20090099228-A1 PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2009-04-16 US disclosed
US-20090099228-A1 PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2009-04-16 US disclosed
WO-2008078291-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-03 WO disclosed
WO-2007122591-A2 PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2007-11-01 WO disclosed
EP-0949238-A1 SUBSTITUTED PROPIONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES HCRTR1, HCRTR2, NPY5R CNR1 6/4885SKP2 3200/4885KCNH2 646/4885
US-20090099228-A1 PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR CNR1 31/4885SKP2 963/4885KCNH2 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.